Meeting
2023 ASCO Annual Meeting
Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.
Authors
Paul David Harker-Murray
Children’s Wisconsin, Milwaukee, WI
Paul David Harker-Murray , Peter D. Cole , Bradford S. Hoppe , David C. Hodgson , Auke Beishuizen , Nathalie Garnier , Salvatore Buffardi , Maurizio Mascarin , Andrej Lissat , Alev Akyol , Russell Crowe , Ju Li , Richard A. Drachtman , Kara M Kelly , Thierry Leblanc , Stephen Daw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02927769
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7515)
DOI
10.1200/JCO.2023.41.16_suppl.7515
Abstract #
7515
Poster Bd #
66
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.
First Author: Peter D. Cole
Poster
2023 ASCO Annual Meeting
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
First Author: David Lavie
Poster
2022 ASCO Annual Meeting
Outcomes of classic Hodgkin lymphoma, relapsed within one year of diagnosis, in the era of novel agents.
First Author: Sanjal Desai
Poster
2016 ASCO Annual Meeting
Outcomes in patients with relapsed/refractory Hodgkin lymphoma (RR-HL) with progression after autologous stem cell transplantation in the current era of novel therapeutics.
First Author: Steven Michael Bair